FBIOFortress Biotech, Inc.
2.870USD+0.70%Mkt Cap: 95.72M $P/E: 1.043d ago
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule fo…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
| Headline | Source | Time |
|---|---|---|
Older | ||
 Fortress Biotech, Inc. Q2 2026 Earnings Call Summary Moby summary of Fortress Biotech, Inc.'s Q2 2026 earnings call | ||
 Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript Emrosi prescriptions jumped 20% sequentially with payer coverage climbing to 38%. | ||
 Fortress Biotech Q2 Earnings Call Highlights Journey Medical reported higher second-quarter revenue and improved profitability, driven by continued prescription growth and improving payer reimbursement for its rosacea treatment Emrosi. Chief Executive Officer Claude Maraoui said the company generated positive EBITDA in the second quarter and | ||